AU2001271066A1 - Method for screening ligand having biological activity - Google Patents

Method for screening ligand having biological activity

Info

Publication number
AU2001271066A1
AU2001271066A1 AU2001271066A AU7106601A AU2001271066A1 AU 2001271066 A1 AU2001271066 A1 AU 2001271066A1 AU 2001271066 A AU2001271066 A AU 2001271066A AU 7106601 A AU7106601 A AU 7106601A AU 2001271066 A1 AU2001271066 A1 AU 2001271066A1
Authority
AU
Australia
Prior art keywords
biological activity
screening ligand
ligand
screening
biological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271066A
Inventor
Hideki Adachi
Kunihiro Hattori
Yasushi Shimonaka
Naohiro Yabuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AU2001271066A1 publication Critical patent/AU2001271066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AU2001271066A 2000-07-17 2001-07-17 Method for screening ligand having biological activity Abandoned AU2001271066A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000221070 2000-07-17
JP2000-221070 2000-07-17
JP2001-159032 2001-05-28
JP2001159032 2001-05-28
PCT/JP2001/006170 WO2002006838A1 (en) 2000-07-17 2001-07-17 Method for screening ligand having biological activity

Publications (1)

Publication Number Publication Date
AU2001271066A1 true AU2001271066A1 (en) 2002-01-30

Family

ID=26596454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271066A Abandoned AU2001271066A1 (en) 2000-07-17 2001-07-17 Method for screening ligand having biological activity

Country Status (5)

Country Link
US (1) US7732133B2 (en)
EP (1) EP1304573A4 (en)
JP (1) JP4908721B2 (en)
AU (1) AU2001271066A1 (en)
WO (1) WO2002006838A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006180705A (en) * 2003-03-06 2006-07-13 Chugai Pharmaceut Co Ltd Chimeric receptor and method for screening ligand or inhibitor for the receptor
WO2005035754A1 (en) 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
ATE427759T1 (en) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc TREATMENT OF OBESITY AND RELATED DISEASES
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
US20110038854A1 (en) * 2006-03-30 2011-02-17 University Of Medicine And Dentistry Of New Jersey Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP2008102117A (en) 2006-09-21 2008-05-01 Fujifilm Corp Surface plasmon enhanced fluorescence sensor and fluorescence detecting method
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
WO2012067176A1 (en) 2010-11-17 2012-05-24 中外製薬株式会社 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
KR102441231B1 (en) 2013-09-27 2022-09-06 추가이 세이야쿠 가부시키가이샤 Method for producing polypeptide heteromultimer
TWI701435B (en) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 Method to determine the reactivity of FVIII
TWI700300B (en) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 Antibodies that neutralize substances with the function of FVIII coagulation factor (FVIII)
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
MA46200A (en) 2016-09-06 2019-07-17 Chugai Pharmaceutical Co Ltd METHODS FOR USING A BISPECIFIC ANTIBODY WHICH RECOGNIZES COAGULATION FACTOR IX AND / OR COAGULATION FACTOR IX ACTIVATED AND COAGULATION FACTOR X AND / OR COAGULATION FACTOR X ACTIVATED
KR20190142775A (en) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Immune Cells Expressing Engineered Antigen Receptors
AR113142A1 (en) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd MULTISPECIFIC ANTIGEN BINDING MOLECULES THAT HAVE SUBSTITUTION ACTIVITY FOR THE COFACTOR FUNCTION OF BLOOD COAGULATION FACTOR VIII (FVIII), AND PHARMACEUTICAL FORMULATIONS CONTAINING SUCH ACTIVE MOLECULE AS INGREDIENT

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3514272A1 (en) * 1985-04-17 1986-10-23 Schering AG, 1000 Berlin und 4709 Bergkamen DERMATICA
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
ATE181928T1 (en) * 1990-03-23 1999-07-15 Osaka Bioscience Inst DNA CODING FOR THE GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR
ATE313321T1 (en) 1991-08-23 2006-01-15 Nps Pharma Inc CALCIUM RECEPTOR ACTIVE COMPOUNDS
JPH08508889A (en) 1993-06-07 1996-09-24 アムジエン・インコーポレーテツド Hybrid receptor molecule
CA2220715C (en) * 1995-06-07 2004-11-02 Praecis Pharmaceuticals Incorporated Functional bioassay for g-protein coupled receptor agonists and antagonists
US5866341A (en) * 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
AU7451500A (en) * 1999-10-06 2001-05-10 Sumitomo Chemical Company, Limited Methods of evaluating whether a test agent is an agent affecting a leptin receptor

Also Published As

Publication number Publication date
EP1304573A1 (en) 2003-04-23
US20040091876A1 (en) 2004-05-13
US7732133B2 (en) 2010-06-08
JP4908721B2 (en) 2012-04-04
WO2002006838A1 (en) 2002-01-24
EP1304573A4 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
AU2001271066A1 (en) Method for screening ligand having biological activity
EP1469316A2 (en) Screening method
EP1113094A3 (en) Plating analysis method
MXPA01010625A (en) Method for down-regulating il5 activity.
HUP0402231A3 (en) A method for determining the biological activity defibrotide
AU7433900A (en) Screening methods
AU2001267978A1 (en) Method for analyzing words
AU2308900A (en) Analysis method
AU4051800A (en) Method for preparing and screening catalysts
AU2002237261A1 (en) Rapid method for screening compounds for in vivo activity
AU1553101A (en) Screening method
IL137371A0 (en) Gene expression methods for screening compounds
GB9923075D0 (en) Screening method
AU2001230365A1 (en) Method of screening compounds for biological activity
AU6429000A (en) Screening method
AU2001268514A1 (en) Method for screening dna binding
AU2001283111A1 (en) Electrolytic system and methods for screening catalytic material
AU5039200A (en) Reciprocating biological filter
AU2002247215A1 (en) Method for screening compounds
AU2002258787A1 (en) Screening methods for identifying ligands
AU2872501A (en) Screening method
AU2001261259A1 (en) Diagnostic method for screening complement regulatory protein levels
AU4856501A (en) Screening method for compounds
AU1704000A (en) Method for diagnostic screening
GB9930255D0 (en) Screening method